• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    An optically-enriched piperidine-2-carboxanlidecompound, in which the piperidine is optionally N-alkylated, is racemised by heating the compound in an aqueous medium, provided that the medium includes an organic co-solvent if the compound is N-alkylated. This process is particularly valuable, in conjunction with a resolution process, for the manufacture of levobupivacaine.
    公开号:US20010000522A1
    申请号:US09/740,152
    申请日:2000-12-18
    公开日:2001-04-26
    发明作者:Ulrich Dyer；Marianne Langston；Martin Woods
    申请人:Dyer Ulrich Conrad；Marianne Langston；Martin Woods；
    IPC主号:C07D211-60
    专利说明:
    [1] 1. This invention relates to the racemisation of optically-enriched piperidine-2-carboxanilides. In particular, the process is suitable for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents. BACKGROUND OF THE INVENTION
    [2] 2. Compounds of formula 1
    [3] 3. wherein R2 is 2,6-dimethylphenyl and R1 is methyl (mepivacaine), n-propyl (ropivacaine as S-enantiomer) or n-butyl (bupivacaine) are widely used as local anaesthetics. The corresponding compound when R1 is H is a useful intermediate.
    [4] 4. Biological studies have shown that the (S)-enantiomers of such N-alkyl-piperidine-2-carboxanilides display lower cardiotoxicity than the corresponding racemates, whilst maintaining the same anaesthetic potency, and are therefore more beneficial for clinical uses. Thus there is a requirement for efficient processes to manufacture compounds of formula 1 in the form of single enantiomers. For this purpose, conventional resolution approaches invariably afford up to 50% of the unwanted enantiomer. To improve atom utilisation in such processes, it is desirable to recycle the unwanted enantiomer by effecting its racemisation in order to provide material suitable for subsequent resolution.
    [5] 5. Friberger et al, Acta. Pharm. Suec. (1971) 8:361-364, report a study of the solubility and partition coefficients of the racemates and enantiomers of mepivacaine and bupivacaine. It is reported that racemic bupivacaine is more soluble than the isomers at a pH above 6. All of the compounds tested have solubilities decreasing to low levels, especially for bupivacaine, at pH values approaching neutrality.
    [6] 6. Fyhr et al, Acta.Pharm.Suec. (1988) 25:121-132, report the racemisation of optically-enriched ropivacaine hydrochloride in dilute aqueous solution at pH 1-6 and 80-130° C. HCl or citric acid was present, in order to establish the pH. The conclusions of this pre-formulation stability study were that the racemisation involves hydroxyl ion-catalysed racemisation of the N-protonated species. This study provides no useful indication as to how to conduct racemisation as such, and does not suggest any volume-efficient commercial process. SUMMARY OF THE INVENTION
    [7] 7. The present invention is based on the surprising discovery that piperidine-2-carboxanilides, including compounds of formula 1 wherein R1 is H, methyl, n-propyl or n-butyl and R2 is 2,6-dimethylphenyl, undergo rapid racemisation when heated in aqueous solution, provided that an organic cosolvent is present when R1 is not H. The practical nature of this discovery is evident in that much more concentrated systems can be used than in the prior art.
    [8] 8. Whereas, at concentrations of 30 mg/ml, at a pH above 5, the use of conditions otherwise specified by Fyhr et al lead to complete inhibition of racemisation of ropivacaine and bupivacaine, the rate of racemisation can be increased, under the conditions used in this invention, with increasing pH of the solution. Racemisation occurs most efficiently at a pH greater than 6, without loss of solubility, which means that no acid need be added. DESCRIPTION OF THE INVENTION
    [9] 9. The reaction can be carried out in water alone, when R1 is H. In this case, a preferred embodiment of the invention is the racemisation of optically-enriched 2′,6′-dimethylpiperidine-2-carboxanilide (1: R1═H, R2═2,6-dimethylphenyl).
    [10] 10. Alternatively, for N-alkylpiperidine compounds of formula 1, the reaction is carried out in the presence of an organic cosolvent such as an alcohol or polyol, e.g. ethylene glycol thus allowing solutions of higher concentration to be used, than in the prior art. A preferred embodiment of this aspect of the invention is the racemisation of optically-enriched bupivacaine in ethylene glycol containing 10% v/v water. The presence of salt forms of compounds of formula 1 does not impede the efficiency of the racemisation process.
    [11] 11. The reaction conditions may comprise heating, as desired. Suitable conditions will depend on the nature of the reactants, but can be readily chosen by those skilled in the art.
    [12] 12. In summary, the present invention establishes simple and economical processes for the racemisation of piperidine-2-carboxanilides, in either neat aqueous media or aqueous media combined with inert organic cosolvents. The invention is particularly suited to the optimum utilisation of unwanted enantiomer in the preparation of enantiopure therapeutic agents, and therefore in practice the starting material will usually be richer in the (R)-enantiomer. When R1 is H, a compound of formula 1 is an intermediate en route to anaesthetic agents. When R1 is n-butyl, the present invention is of particular utility for preparing (S)-bupivacaine, in conjunction with a resolution process, e.g. that described in PCT/GB95/02513 and South African Application No. 95/8993.
    [13] 13. The following Examples illustrate the invention. EXAMPLE 1
    [14] 14. (S)-2′,6′-Dimethylpiperidine-2-carboxanilide (>99% ee, 155 mg, 0.67 mmol) was dissolved in water (14.5 ml). The pH was measured to be 9.97. The solution was heated under reflux for 19 hours. Aqueous ammonia (28% w/v; 1 ml) was added to the cooled solution and the mixture extracted with ethyl acetate (2×20 ml). The combined organic layers were dried with magnesium sulphate and the solvent removed under reduced pressure to give a white crystalline solid (128 mg). Analysis by chiral HPLC showed this to be racemic 2′,6′-dimethylpiperidine-2-carboxanilide. EXAMPLE 2
    [15] 15. A mixture of (S)-bupivacaine (>99% ee, 1.5 g mmol), ethylene glycol (13.5 ml) and water (1.5 ml) was heated at 138° C. for 9 hours. On cooling to ambient temperature crystallisation of a solid occurred. The solid was filtered to give a quantitative yield of bupivacaine which was shown by chiral HPLC analysis to be a 52:48 mixture of (S)-bupivacaine and (R)-bupivacaine. EXAMPLE 3
    [16] 16. (S)-Bupivacaine (>99% ee, 0.27 g, 0.94 mmol) and (S)-bupivacaine (−)-tartrate (2:1 salt, 0.23 g, 0.32 mmol) were heated at 150° C. in propan-2-ol (2.5 ml) and water (2.5 ml) in a sealed vessel for 22 hours. A portion of solution was removed, basified with 28% aqueous ammonia and extracted into heptane. The organic solution was dried with magnesium sulphate and the solvent removed under reduced pressure. The residue was shown by chiral HPLC to be a 63:37 mixture of (S)-bupivacaine and (R)-bupivacaine.
    权利要求:
    Claims (8)
    [1" id="US-20010000522-A1-CLM-00001] 1. A process for the racemisation of an optically-enriched compound
    [2" id="US-20010000522-A1-CLM-00002] 2. The process according to
    claim 1 , wherein said compound is enriched in the (R)-enantiomer.
    [3" id="US-20010000522-A1-CLM-00003] 3. The process according to
    claim 1 , wherein the cosolvent is an alcohol or polyol.
    [4" id="US-20010000522-A1-CLM-00004] 4. The process according to
    claim 3 , wherein the cosolvent is an ethylene glycol.
    [5" id="US-20010000522-A1-CLM-00005] 5. The process according to
    claim 1 , wherein the concentration of the compound in the medium is at least 100 mg/ml.
    [6" id="US-20010000522-A1-CLM-00006] 6. The process according to
    claim 1 , wherein R1 is n-butyl, for preparing bupivacaine of diminished optical purity.
    [7" id="US-20010000522-A1-CLM-00007] 7. The process according to
    claim 1 , wherein R1 is n-propyl.
    [8" id="US-20010000522-A1-CLM-00008] 8. A process for preparing (S)-bupivacaine, which comprises resolving a mixture of enantiomers of bupivacaine, separating (S)-bupivacaine, and racemising residual (R)-bupivacaine, prior to further resolution; wherein said racemisation of residual (R)-bupivacaine comprises heating the compound in an aqueous medium which includes an organic cosolvent, and recovering the product that is precipitated, on cooling.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0812827B1|2009-09-02|Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation
    US6384227B2|2002-05-07|Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents
    US20060014793A1|2006-01-19|Process and diastereomeric salts useful for the optical resolution of racemic alpha-| phenyl] -4- | -1-piperidinebutanol and derivative compounds
    US7482464B2|2009-01-27|Processes for the preparation of S-|-amlodipine
    EP0804417B1|2003-06-04|Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents
    CA2200355C|2007-03-06|Crystallisation of levobupivacaine and analogues thereof
    EA015801B1|2011-12-30|Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates
    HU9900798A2|1999-07-28|Optical resolution of methylphenidate by o,o'-bisaroyl tartaric acids
    EP0782569A1|1997-07-09|Racemisation and asymmetric transformation processes used in the manufacture of levobupivacaine and analogues thereof
    US5965734A|1999-10-12|Processes and intermediates for preparing 2-substituted piperidine stereoisomers
    JP3819532B2|2006-09-13|Piperidine derivatives and method for producing the same
    EP1341762A1|2003-09-10|Process for resolving racemic mixtures of piperidine derivatives
    EP0784608B1|1999-12-22|The manufacture of levobupivacaine and analogues thereof from l-lysine
    JP2005075754A|2005-03-24|Method for optical resolution of trans-1,2-bis|-1,2-ethanediamine
    US20040039206A1|2004-02-26|Process for resolving racemic mixtures of piperidine derivatives
    KR100472609B1|2005-07-07|Crystallization of Levo-Bupivacaine and Its Analogs
    KR20030047466A|2003-06-18|Optical resolution of racemic piperidine carboxylic acid derivative
    KR20040067214A|2004-07-30|Preparing Method for |-1,4- dihydropyridine
    KR20090041194A|2009-04-28|Method for preparing an optically active 1-[|phenylmethyl] -piperazine
    同族专利:
    公开号 | 公开日
    US6384227B2|2002-05-07|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2005091862A3|2004-03-10|2006-04-27|Gelcore Llc|Phosphor and blends thereof for use in leds|
    US20080082038A1|2006-09-28|2008-04-03|Vance Products Incorporated, D/B/A/ Cook Urological Incorporated|Medical Device including a Bioactive in a Non-ionic and an Ionic Form and Methods of Preparation Thereof|
    US20080081829A1|2006-09-28|2008-04-03|Med Institute, Inc|Medical Device Including an Anesthetic and Method of Preparation Thereof|
    US20080108824A1|2006-09-28|2008-05-08|Med Institute, Inc|Medical Devices Incorporating a Bioactive and Methods of Preparing Such Devices|
    US20080167630A1|2004-09-17|2008-07-10|Durect Corporation|Controlled delivery system|
    US20080206321A1|2002-12-13|2008-08-28|Durect Corporation|Oral drug delivery system|
    US20090215808A1|2007-12-06|2009-08-27|Su Il Yum|Oral pharmaceutical dosage forms|
    US20100260844A1|2008-11-03|2010-10-14|Scicinski Jan J|Oral pharmaceutical dosage forms|
    US8956644B2|2006-11-03|2015-02-17|Durect Corporation|Transdermal delivery systems|
    US9555113B2|2013-03-15|2017-01-31|Durect Corporation|Compositions with a rheological modifier to reduce dissolution variability|
    US10471002B2|2002-06-25|2019-11-12|Durect Corporation|Short duration depot formulations|
    US11083796B2|2005-07-26|2021-08-10|Durect Corporation|Peroxide removal from drug delivery vehicle|FR2301498B3|1975-02-20|1978-11-10|Maggioni & C Spa||
    AT214695T|1994-09-23|2002-04-15|Darwin Discovery Ltd|RACEMIZATION PROCESS IN THE PRODUCTION OF LEVOBUPIVACAINE AND ANALOGS|BRPI0104491B8|2001-10-10|2021-05-25|Cristalia Produtos Quim Farmaceuticos Ltda|n--1-propyl-2-piperidinecarboxamide; process of obtaining the enantiomers; non-racemic mixture of anantiomers and its process of obtaining and pharmaceutical composition.|
    法律状态:
    2002-04-19| STCF| Information on status: patent grant|Free format text: PATENTED CASE |
    2003-05-06| CC| Certificate of correction|
    2005-10-14| FPAY| Fee payment|Year of fee payment: 4 |
    2009-10-07| FPAY| Fee payment|Year of fee payment: 8 |
    2013-10-09| FPAY| Fee payment|Year of fee payment: 12 |
    优先权:
    申请号 | 申请日 | 专利标题
    GB9501071.6||1995-01-18||
    GB9501071||1995-01-18||
    GBGB9501071.6A|GB9501071D0|1995-01-18|1995-01-18|Racemisation|
    US87563697A| true| 1997-07-16|1997-07-16||
    US39662899A| true| 1999-09-15|1999-09-15||
    US09/740,152|US6384227B2|1995-01-18|2000-12-18|Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents|US09/740,152| US6384227B2|1995-01-18|2000-12-18|Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents|
    [返回顶部]